Sunitinib malate and Septic shock - a phase IV clinical study of FDA data

Summary:

Septic shock is reported as a side effect among people who take Sunitinib malate (sunitinib malate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Furosemide, and have Gastrointestinal stromal tumor.

The phase IV clinical study analyzes which people have Septic shock when taking Sunitinib malate. It is created by eHealthMe based on reports of 9,155 people who have side effects when taking Sunitinib malate from the FDA, and is updated regularly.

What is Sunitinib malate?

Sunitinib malate has active ingredients of sunitinib malate. eHealthMe is studying from 9,160 Sunitinib malate users. Check the latest studies of Sunitinib malate.

What is Septic shock?

Septic shock (shock due to blood infection) is found to be associated with 1,731 drugs and 3,400 conditions by eHealthMe. Check the latest studies of Septic shock.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 03, 2026

9,155 people reported to have side effects when taking Sunitinib malate.
Among them, 54 people (0.59%) have Septic shock.

Could Sunitinib malate cause Septic shock?

Among these 54 people:

How long have people been on Sunitinib malate when they have Septic shock? *

What is the gender of people who have Septic shock when taking Sunitinib malate? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Septic shock when taking Sunitinib malate? *

What are other drugs people take besides Sunitinib malate? *

What are other side effects people have besides Septic shock? *

Pneumonia: 10 people, 18.52%
Hepatic Failure (liver failure): 8 people, 14.81%
Drug Ineffective: 8 people, 14.81%
Malignant Neoplasm Progression (cancer tumour came back): 7 people, 12.96%
Fatigue (feeling of tiredness): 7 people, 12.96%
Thrombocytopenia (decrease of platelets in blood): 7 people, 12.96%
Cardiac Failure: 6 people, 11.11%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 6 people, 11.11%
Heart Attack: 6 people, 11.11%
Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight): 6 people, 11.11%

What are the existing conditions these people have? *

Gastrointestinal Stromal Tumor: 13 people, 24.07%
Indigestion: 7 people, 12.96%
Stress And Anxiety: 7 people, 12.96%
Renal Cell Carcinoma (a kidney cancer): 6 people, 11.11%
High Blood Pressure: 6 people, 11.11%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 6 people, 11.11%
Colon Cancer: 5 people, 9.26%
Oedema (fluid collection in tissue): 5 people, 9.26%
Prostate Cancer: 4 people, 7.41%
Depression: 4 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Sunitinib malate and have Septic shock?

- Check whether Septic shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sunitinib malate:

Sunitinib malate (9,160 reports)

Septic shock treatments and more:

Septic shock (51,128 reports)

Browse all side effects of Sunitinib malate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Septic shock:

Septic shock (1,731 drugs)

Browse all the conditions that are associated with Septic shock:

Septic shock (3,400 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sunitinib malate (the active ingredients of Sunitinib malate) and Sunitinib malate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.